Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
Kimberley El, Jonathan D. Douros, Francis S. Willard, et al.
Nature Metabolism (2023) Vol. 5, Iss. 6, pp. 945-954
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications
Jonathan E. Campbell, Timo D. Müller, Brian Finan, et al.
Cell Metabolism (2023) Vol. 35, Iss. 9, pp. 1519-1529
Open Access | Times Cited: 60
Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022
Jonathan H. Watanabe, Jimmy Kwon, Bin Nan, et al.
Journal of the American Pharmacists Association (2023) Vol. 64, Iss. 1, pp. 133-138
Open Access | Times Cited: 60
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Maximilian Huttasch, Michael Roden, S. Kahl
Metabolism (2024) Vol. 157, pp. 155937-155937
Open Access | Times Cited: 37
Transforming obesity: The advancement of multi-receptor drugs
Christine M. Kusminski, Diego Pérez–Tilve, Timo D. Müller, et al.
Cell (2024) Vol. 187, Iss. 15, pp. 3829-3853
Closed Access | Times Cited: 27
Futile cycles: Emerging utility from apparent futility
Anand K. Sharma, Radhika Khandelwal, Christian Wolfrum
Cell Metabolism (2024) Vol. 36, Iss. 6, pp. 1184-1203
Open Access | Times Cited: 26
The Role of G Protein–Coupled Receptors and Receptor Kinases in Pancreaticβ-Cell Function and Diabetes
Matthew J. Varney, Jeffrey Benovic
Pharmacological Reviews (2024) Vol. 76, Iss. 2, pp. 267-299
Open Access | Times Cited: 21
Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide
Fatemeh Taktaz, Rosaria Anna Fontanella, Lucia Scisciola, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 17
Glucose-dependent insulinotropic polypeptide (GIP)
Timo D. Müller, Alice E. Adriaenssens, Bo Ahrén, et al.
Molecular Metabolism (2025) Vol. 95, pp. 102118-102118
Open Access | Times Cited: 3
Islet hormones at the intersection of glucose and amino acid metabolism
Phillip J. White, Nicolai J. Wewer Albrechtsen, Jonathan E. Campbell
Nature Reviews Endocrinology (2025)
Closed Access | Times Cited: 2
Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice
Arkadiusz Liśkiewicz, Ahmed Khalil, Daniela Liśkiewicz, et al.
Nature Metabolism (2023) Vol. 5, Iss. 12, pp. 2075-2085
Open Access | Times Cited: 39
The importance of glucose‐dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide
Lærke S. Gasbjerg, Mette M. Rosenkilde, Juris J. Meier, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 11, pp. 3079-3092
Closed Access | Times Cited: 24
Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
Robert M. Gutgesell, Rubén Nogueiras, Matthias H. Tschöp, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 5, pp. 1069-1084
Open Access | Times Cited: 14
GLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells
Ali H. Shilleh, Katrina Viloria, Johannes Broichhagen, et al.
Peptides (2024) Vol. 175, pp. 171179-171179
Open Access | Times Cited: 11
Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics
Jinliang Liang, Huanyi Liu, Guo Lv, et al.
Lipids in Health and Disease (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 1
GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation
Maedeh Movahednasab, Hassan Dianat‐Moghadam, Sana Khodadad, et al.
Diabetology & Metabolic Syndrome (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 1
GLP-1 and GIP receptors signal through distinct β-arrestin 2-dependent pathways to regulate pancreatic β cell function
Nour Zaïmia, Joëlle Obeid, Annie Varrault, et al.
Cell Reports (2023) Vol. 42, Iss. 11, pp. 113326-113326
Open Access | Times Cited: 20
Gut hormones and bone homeostasis: potential therapeutic implications
Béatrice Bouvard, Guillaume Mabilleau
Nature Reviews Endocrinology (2024)
Closed Access | Times Cited: 8
Tirzepatide shows neuroprotective effects via regulating brain glucose metabolism in APP/PS1 mice
Shaobin Yang, Xiaoqian Zhao, Yimeng Zhang, et al.
Peptides (2024) Vol. 179, pp. 171271-171271
Closed Access | Times Cited: 8
Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities
Riccardo Sarzani, Matteo Landolfo, Chiara Di Pentima, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 6
The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice
Leticia Forny Germano, Jacqueline A. Koehler, Laurie L. Baggio, et al.
Molecular Metabolism (2024) Vol. 89, pp. 102019-102019
Open Access | Times Cited: 6
Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don’t
Aaron Novikoff, Timo D. Müller
Physiology (2024) Vol. 39, Iss. 3, pp. 142-156
Closed Access | Times Cited: 6
Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test
Kieren J. Mather, Andrea Mari, Tim Heise, et al.
The Journal of Clinical Endocrinology & Metabolism (2024) Vol. 109, Iss. 12, pp. 3046-3054
Open Access | Times Cited: 5
Hepatic function of glucagon-like peptide-1 and its based diabetes drugs
Jia Nuo Feng, Tianru Jin
Medical Review (2024) Vol. 4, Iss. 4, pp. 312-325
Open Access | Times Cited: 5
Altered desensitization and internalization patterns of rodent versus human glucose‐dependent insulinotropic polypeptide (GIP) receptors. An important drug discovery challenge
Lærke S. Gasbjerg, Rasmus Syberg Rasmussen, Adrian Dragan, et al.
British Journal of Pharmacology (2024)
Open Access | Times Cited: 5
The dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice
Pedro H. Reis‐Barbosa, Ilitch Aquino Marcondes‐de‐Castro, Thatiany de Souza Marinho, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 10, pp. 4613-4621
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top